At a Glance
- Company: QuantX Biosciences, Inc.
- Locations: Princeton, NJ & Shanghai, China
- Deal value: $85m Series B (total funding $130m)
- Focus area: Oral small-molecule immunology/inflammation therapeutics
- Next steps: IND-enabling studies for STAT6/IL-17 inhibitors; discovery expansion
What happened?
QuantX Biosciences closed an oversubscribed $85 million Series B financing on 9 February 2026, co-led by LAV and Sanofi Ventures with participation from Hongshan and existing investors. The proceeds will fund clinical development of its lead oral STAT6 inhibitor (asthma/atopic dermatitis) and oral IL-17 inhibitor (psoriasis/hidradenitis suppurativa), plus continued discovery platform expansion.
Why does it matter?
QuantX’s physics-based computational platform accelerates oral small-molecule design for validated immuno-inflammatory targets, potentially delivering best-in-class assets faster than traditional screening. The funding validates AI/ML integration in early discovery amid pharma demand for differentiated orals in large indications.
Who’s behind it?
Founded 2022 by Wayne Tang/Yax Sun and incubated by OrbiMed/Creacion Ventures, QuantX combines modelling, HPC and chemistry to optimise candidates. Interim CEO Wei Li highlighted rapid advancement of multiple first-in-class molecules to IND-enabling studies in three years.
How was it achieved?
Proceeds advance two clinical-stage candidates through IND-enabling toxicology and CMC while scaling the discovery engine for additional immunology/inflammation programmes.
What’s next?
STAT6 inhibitor enters human studies end-2026; IL-17 inhibitor phase 1 early 2027. Platform expansion targets broader immuno-inflammatory diseases.
What are people saying?
Wei Li: “Watershed moment… refine discovery engine… advance multiple programs toward human studies.” David Wang, OrbiMed: “Deliver best-in-class assets… unique value proposition.”